-
1
-
-
0037260139
-
Cancer statistics, 2003
-
Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
-
(2003)
CA Cancer J Clin
, vol.53
, pp. 5-26
-
-
Jemal, A.1
Murray, T.2
Samuels, A.3
Ghafoor, A.4
Ward, E.5
Thun, M.J.6
-
3
-
-
78651456659
-
-
Ministry of Health, Labour and Welfare. Japanese Government: vital statistics of Japan
-
Ministry of Health, Labour and Welfare. Japanese Government: vital statistics of Japan2009. Available from: http://ganjoho.ncc.go.jp/professional/ statistics/odjrh3000000hwsa-att/cancer-mortality(1958- 2008).xls.
-
(2009)
-
-
-
4
-
-
33947593200
-
-
American Cancer Society, Atlanta, GA: American Cancer Society
-
American Cancer Society. Cancer Facts and Figures2007. Atlanta, GA: American Cancer Society; 2007. p. 16-7.
-
(2007)
Cancer Facts and Figures 2007
, pp. 16-17
-
-
-
5
-
-
0028888708
-
Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?
-
Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995;221:59-66.
-
(1995)
Ann Surg
, vol.221
, pp. 59-66
-
-
Nitecki, S.S.1
Sarr, M.G.2
Colby, T.V.3
Van Heerden, J.A.4
-
6
-
-
0022657154
-
Collective review of small carcinomas of the pancreas
-
Tsuchiya R, Noda T, Harada N, Miyamoto T, Tomioka T, Yamamoto K, et al. Collective review of small carcinomas of the pancreas. Ann Surg 1986;203:77-81.
-
(1986)
Ann Surg
, vol.203
, pp. 77-81
-
-
Tsuchiya, R.1
Noda, T.2
Harada, N.3
Miyamoto, T.4
Tomioka, T.5
Yamamoto, K.6
-
7
-
-
0032760453
-
AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma
-
American Gastroenterological Association
-
DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999;117:1464-84.
-
(1999)
Gastroenterology
, vol.117
, pp. 1464-1484
-
-
Dimagno, E.P.1
Reber, H.A.2
Tempero, M.A.3
-
8
-
-
45749089796
-
Metastatic pancreatic cancer 2008: Is the glass less empty?
-
Nieto J, Grossbard ML, Kozuch P. Metastatic pancreatic cancer 2008: is the glass less empty?Oncologist 2008;13:562-76.
-
(2008)
Oncologist
, vol.13
, pp. 562-576
-
-
Nieto, J.1
Grossbard, M.L.2
Kozuch, P.3
-
9
-
-
8244254377
-
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
-
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15: 2403-13.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2403-2413
-
-
Burris III, H.A.1
Moore, M.J.2
Andersen, J.3
Green, M.R.4
Rothenberg, M.L.5
Modiano, M.R.6
-
10
-
-
68949114505
-
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group
-
Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:3778-85.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3778-3785
-
-
Poplin, E.1
Feng, Y.2
Berlin, J.3
Rothenberg, M.L.4
Hochster, H.5
Mitchell, E.6
-
11
-
-
78651419575
-
-
NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma V.1. National Comprehensive Cancer Network; 2009
-
NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma V.1. National Comprehensive Cancer Network; 2009
-
-
-
-
12
-
-
22844448456
-
Molecular markers of early pancreatic cancer
-
Goggins M. Molecular markers of early pancreatic cancer. J Clin Oncol 2005;23:4524-31.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4524-4531
-
-
Goggins, M.1
-
13
-
-
0033845951
-
Can we screen high-risk individuals to detect early pancreatic carcinoma?
-
Goggins M, Canto M, Hruban R. Can we screen high-risk individuals to detect early pancreatic carcinoma?J Surg Oncol 2000; 74:243-8.
-
(2000)
J Surg Oncol
, vol.74
, pp. 243-248
-
-
Goggins, M.1
Canto, M.2
Hruban, R.3
-
14
-
-
0037434981
-
Disease proteomics
-
Hanash S. Disease proteomics. Nature 2003;422:226-32.
-
(2003)
Nature
, vol.422
, pp. 226-232
-
-
Hanash, S.1
-
16
-
-
51649106775
-
Distinct gene expression-defined classes of gastrointestinal stromal tumor
-
Yamaguchi U, Nakayama R, Honda K, Ichikawa H, Hasegawa T, Shitashige M, et al. Distinct gene expression-defined classes of gastrointestinal stromal tumor. J Clin Oncol 2008;26:4100-8.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4100-4108
-
-
Yamaguchi, U.1
Nakayama, R.2
Honda, K.3
Ichikawa, H.4
Hasegawa, T.5
Shitashige, M.6
-
17
-
-
33746285299
-
Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry
-
Ono M, Shitashige M, Honda K, Isobe T, Kuwabara H, Matsuzuki H, et al. Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. Mol Cell Proteomics 2006;5:1338-47.
-
(2006)
Mol Cell Proteomics
, vol.5
, pp. 1338-1347
-
-
Ono, M.1
Shitashige, M.2
Honda, K.3
Isobe, T.4
Kuwabara, H.5
Matsuzuki, H.6
-
18
-
-
65549144136
-
Identification of a predictive biomarker for hematologic toxicities of gemcitabine
-
Matsubara J, Ono M, Negishi A, Ueno H, Okusaka T, Furuse J, et al. Identification of a predictive biomarker for hematologic toxicities of gemcitabine. J Clin Oncol 2009;27:2261-8.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2261-2268
-
-
Matsubara, J.1
Ono, M.2
Negishi, A.3
Ueno, H.4
Okusaka, T.5
Furuse, J.6
-
19
-
-
62849128405
-
Large-scale quantitative clinical proteomics by label-free liquid chromatography and mass spectrometry
-
Negishi A, Ono M, Handa Y, Kato H, Yamashita K, Honda K, et al. Large-scale quantitative clinical proteomics by label-free liquid chromatography and mass spectrometry. Cancer Sci 2009;100: 514-9.
-
(2009)
Cancer Sci
, vol.100
, pp. 514-519
-
-
Negishi, A.1
Ono, M.2
Handa, Y.3
Kato, H.4
Yamashita, K.5
Honda, K.6
-
20
-
-
70350400752
-
Prolyl 4-hydroxylation of alpha-fibrinogen: A novel protein modification revealed by plasma proteomics
-
Ono M, Matsubara J, Honda K, Sakuma T, Hashiguchi T, Nose H, et al. Prolyl 4-hydroxylation of alpha-fibrinogen: a novel protein modification revealed by plasma proteomics. J Biol Chem 2009;284:29041-9.
-
(2009)
J Biol Chem
, vol.284
, pp. 29041-29049
-
-
Ono, M.1
Matsubara, J.2
Honda, K.3
Sakuma, T.4
Hashiguchi, T.5
Nose, H.6
-
21
-
-
0001644020
-
The human plasma proteome: History, character, and diagnostic prospects
-
Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1:845-67.
-
(2002)
Mol Cell Proteomics
, vol.1
, pp. 845-867
-
-
Anderson, N.L.1
Anderson, N.G.2
-
22
-
-
33748575600
-
A novel approach and protocol for discovering extremely low-abundance proteins in serum
-
Tanaka Y, Akiyama H, Kuroda T, Jung G, Tanahashi K, Sugaya H, et al. A novel approach and protocol for discovering extremely low-abundance proteins in serum. Proteomics 2006;6:4845-55.
-
(2006)
Proteomics
, vol.6
, pp. 4845-4855
-
-
Tanaka, Y.1
Akiyama, H.2
Kuroda, T.3
Jung, G.4
Tanahashi, K.5
Sugaya, H.6
-
23
-
-
0036649486
-
The role of proteomics in toxicology: Identification of biomarkers of toxicity by protein expression analysis
-
Kennedy S. The role of proteomics in toxicology: identification of biomarkers of toxicity by protein expression analysis. Biomarkers 2002;7:269-90.
-
(2002)
Biomarkers
, vol.7
, pp. 269-290
-
-
Kennedy, S.1
-
24
-
-
0346364695
-
Characterization of the low molecular weight human serum proteome
-
Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003;2:1096-103.
-
(2003)
Mol Cell Proteomics
, vol.2
, pp. 1096-1103
-
-
Tirumalai, R.S.1
Chan, K.C.2
Prieto, D.A.3
Issaq, H.J.4
Conrads, T.P.5
Veenstra, T.D.6
-
25
-
-
78651446737
-
-
Available from
-
Available from: http://www.fhcrc.org/science/international-biomarker/.
-
-
-
-
26
-
-
11144279340
-
Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer
-
Honda K, Yamada T, Hayashida Y, Idogawa M, Sato S, Hasegawa F, et al. Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology 2005;128:51-62.
-
(2005)
Gastroenterology
, vol.128
, pp. 51-62
-
-
Honda, K.1
Yamada, T.2
Hayashida, Y.3
Idogawa, M.4
Sato, S.5
Hasegawa, F.6
-
27
-
-
20444503830
-
Poly (ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex
-
Idogawa M, Yamada T, Honda K, Sato S, Imai K, Hirohashi S. Poly (ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex. Gastroenterology 2005;128:1919-36.
-
(2005)
Gastroenterology
, vol.128
, pp. 1919-1936
-
-
Idogawa, M.1
Yamada, T.2
Honda, K.3
Sato, S.4
Imai, K.5
Hirohashi, S.6
-
28
-
-
77950663765
-
Survival prediction for pancreatic cancer patients receiving gemcitabine treatment
-
Matsubara J, Ono M, Honda K, Negishi A, Ueno H, Okusaka T, et al. Survival prediction for pancreatic cancer patients receiving gemcitabine treatment. Mol Cell Proteomics 2010;9:695-704.
-
(2010)
Mol Cell Proteomics
, vol.9
, pp. 695-704
-
-
Matsubara, J.1
Ono, M.2
Honda, K.3
Negishi, A.4
Ueno, H.5
Okusaka, T.6
-
29
-
-
66649092902
-
Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer
-
Fiedler GM, Leichtle AB, Kase J, Baumann S, Ceglarek U, Felix K, et al. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer. Clin Cancer Res 2009;15:3812-9.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3812-3819
-
-
Fiedler, G.M.1
Leichtle, A.B.2
Kase, J.3
Baumann, S.4
Ceglarek, U.5
Felix, K.6
-
30
-
-
10744223905
-
Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry
-
Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10:860-8.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 860-868
-
-
Koopmann, J.1
Zhang, Z.2
White, N.3
Rosenzweig, J.4
Fedarko, N.5
Jagannath, S.6
-
31
-
-
11144353917
-
Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers
-
Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 2004;10:2386-92.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 2386-2392
-
-
Koopmann, J.1
Buckhaults, P.2
Brown, D.A.3
Zahurak, M.L.4
Sato, N.5
Fukushima, N.6
-
32
-
-
0032784841
-
Usefulness of novel tumour markers
-
Rhodes JM. Usefulness of novel tumour markers. Ann Oncol 1999;10Suppl 4:118-21.
-
(1999)
Ann Oncol
, vol.10
, Issue.SUPPL. 4
, pp. 118-121
-
-
Rhodes, J.M.1
-
33
-
-
33646472556
-
Cancer CXC chemokine networks and tumour angiogenesis
-
Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 2006;42:768-78.
-
(2006)
Eur J Cancer
, vol.42
, pp. 768-778
-
-
Strieter, R.M.1
Burdick, M.D.2
Mestas, J.3
Gomperts, B.4
Keane, M.P.5
Belperio, J.A.6
-
34
-
-
0037424253
-
Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2
-
Heidemann J, Ogawa H, Dwinell MB, Rafiee P, Maaser C, Gockel HR, et al. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem 2003;278:8508-15.
-
(2003)
J Biol Chem
, vol.278
, pp. 8508-8515
-
-
Heidemann, J.1
Ogawa, H.2
Dwinell, M.B.3
Rafiee, P.4
Maaser, C.5
Gockel, H.R.6
-
35
-
-
33846613303
-
Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease
-
Aivado M, Spentzos D, Germing U, Alterovitz G, Meng XY, Grall F, et al. Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci USA 2007;104:1307-12.
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, pp. 1307-1312
-
-
Aivado, M.1
Spentzos, D.2
Germing, U.3
Alterovitz, G.4
Meng, X.Y.5
Grall, F.6
-
36
-
-
67649971550
-
Connective tissue-activating peptide III: A novel blood biomarker for early lung cancer detection
-
Yee J, Sadar MD, Sin DD, Kuzyk M,Xing L, Kondra J, et al. Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol 2009;27:2787-92.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2787-2792
-
-
Yee, J.1
Sadar, M.D.2
Sin, D.D.3
Kuzyk Mxing, L.4
Kondra, J.5
-
37
-
-
0034332187
-
Down-regulation of neutrophil functions by the ELR(+) CXC chemokine platelet basic protein
-
Ehlert JE, Ludwig A, Grimm TA, Lindner B, Flad HD, Brandt E. Down-regulation of neutrophil functions by the ELR(+) CXC chemokine platelet basic protein. Blood 2000;96:2965-72.
-
(2000)
Blood
, vol.96
, pp. 2965-2972
-
-
Ehlert, J.E.1
Ludwig, A.2
Grimm, T.A.3
Lindner, B.4
Flad, H.D.5
Brandt, E.6
-
38
-
-
33646401341
-
Monocyte-derived CXCL7 peptides in the marrow microenvironment
-
Pillai MM, Iwata M, Awaya N, Graf L, Torok-Storb B. Monocyte-derived CXCL7 peptides in the marrow microenvironment. Blood 2006;107:3520-6.
-
(2006)
Blood
, vol.107
, pp. 3520-3526
-
-
Pillai, M.M.1
Iwata, M.2
Awaya, N.3
Graf, L.4
Torok-Storb, B.5
-
39
-
-
31044436630
-
Differential exoprotease activities confer tumor-specific serum peptidome patterns
-
Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116:271-84.
-
(2006)
J Clin Invest
, vol.116
, pp. 271-284
-
-
Villanueva, J.1
Shaffer, D.R.2
Philip, J.3
Chaparro, C.A.4
Erdjument-Bromage, H.5
Olshen, A.B.6
-
40
-
-
0034667542
-
Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact
-
Van Den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000;96:2673-81.
-
(2000)
Blood
, vol.96
, pp. 2673-2681
-
-
Van Den Steen, P.E.1
Proost, P.2
Wuyts, A.3
Van Damme, J.4
Opdenakker, G.5
-
41
-
-
51349092847
-
Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients
-
Tian M, Cui YZ, Song GH, Zong MJ, Zhou XY, Chen Y, et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008;8:241.
-
(2008)
BMC Cancer
, vol.8
, pp. 241
-
-
Tian, M.1
Cui, Y.Z.2
Song, G.H.3
Zong, M.J.4
Zhou, X.Y.5
Chen, Y.6
-
43
-
-
28544446295
-
Possible detection of pancreatic cancer by plasma protein profiling
-
Honda K, Hayashida Y, Umaki T, Okusaka T, Kosuge T, Kikuchi S, et al. Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res 2005;65:10613-22.
-
(2005)
Cancer Res
, vol.65
, pp. 10613-10622
-
-
Honda, K.1
Hayashida, Y.2
Umaki, T.3
Okusaka, T.4
Kosuge, T.5
Kikuchi, S.6
|